Brigatinib (ORR, 42 ~ 67%; median PFS, 9.2 ~ 12.9 months) is a third-generation ALK-TKI and was applied to crizotinib-resistant NSCLC-BM patients [144, 156]. Here, ALK is linked to non-small cell lung carcinoma.